Topic: patent infringement
Sanofi and Regeneron asked a U.S. appeals court to let them continue selling their PCSK9 drug Praluent while a bitter patent dispute with Amgen continues. Analysts aren't optimistic that the partners will prevail.
Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash, plus potential royalties, sending Forward's shares skyward by 83% in premarket trading.
An appeals court ruled against generics challenger Teva, potentially protecting Eli Lilly's cancer med Alimta until 2022.
J.P. Morgan's annual healthcare investor conference is like a bazaar of biopharma news, commentary and behind-the-scenes meetings. Here's a sampling of the #JPM2017 info worth your attention.
The PD-1 inhibitor patent battle raging between Merck and Bristol-Myers Squibb in the U.S., Europe and Australia has now reached Japan.
Pfizer’s divide-and-conquer approach to Lyrica in the U.K. just hit a wall. The Court of Appeal upheld a ruling that struck down a key patent on Lyrica and cleared Actavis’ generic of infringing it.
The U.S. Patent and Trademark Office has upheld the validity of claims related to 5 patents of Mallinckrodt’s Inomax (nitric oxide) gas delivery systems used for inhalation.
Three strikes for the patents on Teva’s long-acting Copaxone formula, but the branded drug isn’t out of the exclusivity game yet.
The University of Minnesota wants a piece of Gilead’s hep C business. The school sued for patent infringement Monday, seeking royalties on the drugs’ multibillion-dollar sales.
It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up, AbbVie has sued Amgen for patent infringement.